nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoprolol—CYP2C19—Tamoxifen—pancreatic cancer	0.087	0.148	CbGbCtD
Metoprolol—ABCB1—Tamoxifen—pancreatic cancer	0.0702	0.119	CbGbCtD
Metoprolol—CYP2D6—Tamoxifen—pancreatic cancer	0.0661	0.112	CbGbCtD
Metoprolol—ABCB1—Gemcitabine—pancreatic cancer	0.0605	0.103	CbGbCtD
Metoprolol—ABCB1—Erlotinib—pancreatic cancer	0.0597	0.101	CbGbCtD
Metoprolol—CYP2D6—Erlotinib—pancreatic cancer	0.0562	0.0954	CbGbCtD
Metoprolol—ABCB1—Irinotecan—pancreatic cancer	0.0539	0.0914	CbGbCtD
Metoprolol—ABCB1—Docetaxel—pancreatic cancer	0.0395	0.067	CbGbCtD
Metoprolol—ABCB1—Sunitinib—pancreatic cancer	0.0393	0.0667	CbGbCtD
Metoprolol—ABCB1—Doxorubicin—pancreatic cancer	0.0294	0.0499	CbGbCtD
Metoprolol—CYP2D6—Doxorubicin—pancreatic cancer	0.0277	0.0471	CbGbCtD
Metoprolol—Dyspepsia—Fluorouracil—pancreatic cancer	0.000402	0.00101	CcSEcCtD
Metoprolol—Nausea—Tamoxifen—pancreatic cancer	0.000401	0.00101	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000401	0.00101	CcSEcCtD
Metoprolol—Fatigue—Gemcitabine—pancreatic cancer	0.0004	0.00101	CcSEcCtD
Metoprolol—Cardiac arrest—Doxorubicin—pancreatic cancer	0.000398	0.001	CcSEcCtD
Metoprolol—Pain—Gemcitabine—pancreatic cancer	0.000397	0.001	CcSEcCtD
Metoprolol—Constipation—Gemcitabine—pancreatic cancer	0.000397	0.001	CcSEcCtD
Metoprolol—Nausea—Erlotinib—pancreatic cancer	0.000397	0.001	CcSEcCtD
Metoprolol—Mood swings—Doxorubicin—pancreatic cancer	0.000396	0.000999	CcSEcCtD
Metoprolol—Diarrhoea—Sunitinib—pancreatic cancer	0.000396	0.000997	CcSEcCtD
Metoprolol—Dysgeusia—Docetaxel—pancreatic cancer	0.000395	0.000996	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000394	0.000993	CcSEcCtD
Metoprolol—Feeling abnormal—Irinotecan—pancreatic cancer	0.000393	0.00099	CcSEcCtD
Metoprolol—Pain—Fluorouracil—pancreatic cancer	0.00039	0.000984	CcSEcCtD
Metoprolol—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.00039	0.000982	CcSEcCtD
Metoprolol—Muscle spasms—Docetaxel—pancreatic cancer	0.000388	0.000978	CcSEcCtD
Metoprolol—Liver function test abnormal—Doxorubicin—pancreatic cancer	0.000386	0.000973	CcSEcCtD
Metoprolol—Dizziness—Sunitinib—pancreatic cancer	0.000383	0.000964	CcSEcCtD
Metoprolol—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000383	0.000964	CcSEcCtD
Metoprolol—Orthostatic hypotension—Doxorubicin—pancreatic cancer	0.000382	0.000963	CcSEcCtD
Metoprolol—Abdominal pain upper—Doxorubicin—pancreatic cancer	0.000382	0.000963	CcSEcCtD
Metoprolol—Angina pectoris—Epirubicin—pancreatic cancer	0.000381	0.000959	CcSEcCtD
Metoprolol—Breast disorder—Doxorubicin—pancreatic cancer	0.000378	0.000953	CcSEcCtD
Metoprolol—Abdominal pain—Irinotecan—pancreatic cancer	0.000377	0.000949	CcSEcCtD
Metoprolol—Body temperature increased—Irinotecan—pancreatic cancer	0.000377	0.000949	CcSEcCtD
Metoprolol—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000376	0.000948	CcSEcCtD
Metoprolol—Vomiting—Sunitinib—pancreatic cancer	0.000368	0.000927	CcSEcCtD
Metoprolol—Body temperature increased—Gemcitabine—pancreatic cancer	0.000367	0.000925	CcSEcCtD
Metoprolol—Rash—Sunitinib—pancreatic cancer	0.000365	0.000919	CcSEcCtD
Metoprolol—Dermatitis—Sunitinib—pancreatic cancer	0.000364	0.000918	CcSEcCtD
Metoprolol—Urticaria—Fluorouracil—pancreatic cancer	0.000363	0.000914	CcSEcCtD
Metoprolol—Headache—Sunitinib—pancreatic cancer	0.000362	0.000913	CcSEcCtD
Metoprolol—Syncope—Docetaxel—pancreatic cancer	0.000362	0.000912	CcSEcCtD
Metoprolol—Leukopenia—Docetaxel—pancreatic cancer	0.000361	0.00091	CcSEcCtD
Metoprolol—Body temperature increased—Fluorouracil—pancreatic cancer	0.000361	0.000909	CcSEcCtD
Metoprolol—Palpitations—Docetaxel—pancreatic cancer	0.000357	0.000899	CcSEcCtD
Metoprolol—Photosensitivity reaction—Epirubicin—pancreatic cancer	0.000357	0.000899	CcSEcCtD
Metoprolol—Weight increased—Epirubicin—pancreatic cancer	0.000356	0.000896	CcSEcCtD
Metoprolol—Loss of consciousness—Docetaxel—pancreatic cancer	0.000355	0.000894	CcSEcCtD
Metoprolol—Angina pectoris—Doxorubicin—pancreatic cancer	0.000352	0.000887	CcSEcCtD
Metoprolol—Hypersensitivity—Irinotecan—pancreatic cancer	0.000351	0.000885	CcSEcCtD
Metoprolol—Pneumonia—Epirubicin—pancreatic cancer	0.00035	0.000883	CcSEcCtD
Metoprolol—Hypertension—Docetaxel—pancreatic cancer	0.000349	0.000878	CcSEcCtD
Metoprolol—Arthralgia—Docetaxel—pancreatic cancer	0.000344	0.000866	CcSEcCtD
Metoprolol—Chest pain—Docetaxel—pancreatic cancer	0.000344	0.000866	CcSEcCtD
Metoprolol—Nausea—Sunitinib—pancreatic cancer	0.000344	0.000866	CcSEcCtD
Metoprolol—Asthenia—Irinotecan—pancreatic cancer	0.000342	0.000862	CcSEcCtD
Metoprolol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000341	0.00086	CcSEcCtD
Metoprolol—Jaundice—Epirubicin—pancreatic cancer	0.00034	0.000856	CcSEcCtD
Metoprolol—Conjunctivitis—Epirubicin—pancreatic cancer	0.000339	0.000853	CcSEcCtD
Metoprolol—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000336	0.000847	CcSEcCtD
Metoprolol—Dry mouth—Docetaxel—pancreatic cancer	0.000336	0.000847	CcSEcCtD
Metoprolol—Sweating—Epirubicin—pancreatic cancer	0.000334	0.000842	CcSEcCtD
Metoprolol—Asthenia—Gemcitabine—pancreatic cancer	0.000333	0.000839	CcSEcCtD
Metoprolol—Confusional state—Docetaxel—pancreatic cancer	0.000332	0.000837	CcSEcCtD
Metoprolol—Photosensitivity reaction—Doxorubicin—pancreatic cancer	0.00033	0.000832	CcSEcCtD
Metoprolol—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.00033	0.00083	CcSEcCtD
Metoprolol—Oedema—Docetaxel—pancreatic cancer	0.000329	0.00083	CcSEcCtD
Metoprolol—Weight increased—Doxorubicin—pancreatic cancer	0.000329	0.000829	CcSEcCtD
Metoprolol—Pruritus—Gemcitabine—pancreatic cancer	0.000328	0.000828	CcSEcCtD
Metoprolol—Diarrhoea—Irinotecan—pancreatic cancer	0.000326	0.000822	CcSEcCtD
Metoprolol—Agranulocytosis—Epirubicin—pancreatic cancer	0.000325	0.000819	CcSEcCtD
Metoprolol—Pneumonia—Doxorubicin—pancreatic cancer	0.000324	0.000817	CcSEcCtD
Metoprolol—Shock—Docetaxel—pancreatic cancer	0.000324	0.000817	CcSEcCtD
Metoprolol—Nervous system disorder—Docetaxel—pancreatic cancer	0.000323	0.000814	CcSEcCtD
Metoprolol—Pruritus—Fluorouracil—pancreatic cancer	0.000323	0.000814	CcSEcCtD
Metoprolol—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000323	0.000813	CcSEcCtD
Metoprolol—Tachycardia—Docetaxel—pancreatic cancer	0.000322	0.00081	CcSEcCtD
Metoprolol—Skin disorder—Docetaxel—pancreatic cancer	0.00032	0.000806	CcSEcCtD
Metoprolol—Bradycardia—Epirubicin—pancreatic cancer	0.000318	0.000802	CcSEcCtD
Metoprolol—Diarrhoea—Gemcitabine—pancreatic cancer	0.000318	0.0008	CcSEcCtD
Metoprolol—Dizziness—Irinotecan—pancreatic cancer	0.000315	0.000794	CcSEcCtD
Metoprolol—Jaundice—Doxorubicin—pancreatic cancer	0.000314	0.000792	CcSEcCtD
Metoprolol—Rhinitis—Epirubicin—pancreatic cancer	0.000314	0.00079	CcSEcCtD
Metoprolol—Conjunctivitis—Doxorubicin—pancreatic cancer	0.000313	0.00079	CcSEcCtD
Metoprolol—Hepatitis—Epirubicin—pancreatic cancer	0.000313	0.000788	CcSEcCtD
Metoprolol—Diarrhoea—Fluorouracil—pancreatic cancer	0.000312	0.000787	CcSEcCtD
Metoprolol—Sweating—Doxorubicin—pancreatic cancer	0.000309	0.000779	CcSEcCtD
Metoprolol—Oedema peripheral—Epirubicin—pancreatic cancer	0.000308	0.000776	CcSEcCtD
Metoprolol—Hypotension—Docetaxel—pancreatic cancer	0.000308	0.000776	CcSEcCtD
Metoprolol—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000307	0.000774	CcSEcCtD
Metoprolol—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.000305	0.000768	CcSEcCtD
Metoprolol—Vomiting—Irinotecan—pancreatic cancer	0.000303	0.000764	CcSEcCtD
Metoprolol—Dizziness—Fluorouracil—pancreatic cancer	0.000302	0.000761	CcSEcCtD
Metoprolol—Visual impairment—Epirubicin—pancreatic cancer	0.000301	0.000759	CcSEcCtD
Metoprolol—Agranulocytosis—Doxorubicin—pancreatic cancer	0.000301	0.000758	CcSEcCtD
Metoprolol—Rash—Irinotecan—pancreatic cancer	0.000301	0.000757	CcSEcCtD
Metoprolol—Dermatitis—Irinotecan—pancreatic cancer	0.0003	0.000756	CcSEcCtD
Metoprolol—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.0003	0.000756	CcSEcCtD
Metoprolol—Headache—Irinotecan—pancreatic cancer	0.000299	0.000752	CcSEcCtD
Metoprolol—Insomnia—Docetaxel—pancreatic cancer	0.000298	0.000751	CcSEcCtD
Metoprolol—Paraesthesia—Docetaxel—pancreatic cancer	0.000296	0.000745	CcSEcCtD
Metoprolol—Vomiting—Gemcitabine—pancreatic cancer	0.000295	0.000744	CcSEcCtD
Metoprolol—Bradycardia—Doxorubicin—pancreatic cancer	0.000295	0.000742	CcSEcCtD
Metoprolol—Dyspnoea—Docetaxel—pancreatic cancer	0.000294	0.00074	CcSEcCtD
Metoprolol—Somnolence—Docetaxel—pancreatic cancer	0.000293	0.000738	CcSEcCtD
Metoprolol—Rash—Gemcitabine—pancreatic cancer	0.000293	0.000738	CcSEcCtD
Metoprolol—Dermatitis—Gemcitabine—pancreatic cancer	0.000292	0.000737	CcSEcCtD
Metoprolol—Eye disorder—Epirubicin—pancreatic cancer	0.000292	0.000737	CcSEcCtD
Metoprolol—Tinnitus—Epirubicin—pancreatic cancer	0.000292	0.000735	CcSEcCtD
Metoprolol—Headache—Gemcitabine—pancreatic cancer	0.000291	0.000733	CcSEcCtD
Metoprolol—Cardiac disorder—Epirubicin—pancreatic cancer	0.00029	0.000731	CcSEcCtD
Metoprolol—Vomiting—Fluorouracil—pancreatic cancer	0.00029	0.000731	CcSEcCtD
Metoprolol—Rhinitis—Doxorubicin—pancreatic cancer	0.00029	0.000731	CcSEcCtD
Metoprolol—Dyspepsia—Docetaxel—pancreatic cancer	0.00029	0.000731	CcSEcCtD
Metoprolol—Hepatitis—Doxorubicin—pancreatic cancer	0.000289	0.000729	CcSEcCtD
Metoprolol—Rash—Fluorouracil—pancreatic cancer	0.000288	0.000725	CcSEcCtD
Metoprolol—Dermatitis—Fluorouracil—pancreatic cancer	0.000288	0.000725	CcSEcCtD
Metoprolol—Headache—Fluorouracil—pancreatic cancer	0.000286	0.000721	CcSEcCtD
Metoprolol—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000285	0.000718	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000284	0.000717	CcSEcCtD
Metoprolol—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000284	0.000717	CcSEcCtD
Metoprolol—Fatigue—Docetaxel—pancreatic cancer	0.000284	0.000716	CcSEcCtD
Metoprolol—Angiopathy—Epirubicin—pancreatic cancer	0.000284	0.000715	CcSEcCtD
Metoprolol—Nausea—Irinotecan—pancreatic cancer	0.000283	0.000713	CcSEcCtD
Metoprolol—Immune system disorder—Epirubicin—pancreatic cancer	0.000283	0.000712	CcSEcCtD
Metoprolol—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000282	0.00071	CcSEcCtD
Metoprolol—Pain—Docetaxel—pancreatic cancer	0.000282	0.00071	CcSEcCtD
Metoprolol—Constipation—Docetaxel—pancreatic cancer	0.000282	0.00071	CcSEcCtD
Metoprolol—Arrhythmia—Epirubicin—pancreatic cancer	0.000279	0.000704	CcSEcCtD
Metoprolol—Visual impairment—Doxorubicin—pancreatic cancer	0.000279	0.000703	CcSEcCtD
Metoprolol—Alopecia—Epirubicin—pancreatic cancer	0.000276	0.000696	CcSEcCtD
Metoprolol—Nausea—Gemcitabine—pancreatic cancer	0.000276	0.000695	CcSEcCtD
Metoprolol—Mental disorder—Epirubicin—pancreatic cancer	0.000274	0.00069	CcSEcCtD
Metoprolol—Feeling abnormal—Docetaxel—pancreatic cancer	0.000272	0.000684	CcSEcCtD
Metoprolol—Nausea—Fluorouracil—pancreatic cancer	0.000271	0.000683	CcSEcCtD
Metoprolol—Eye disorder—Doxorubicin—pancreatic cancer	0.00027	0.000681	CcSEcCtD
Metoprolol—Tinnitus—Doxorubicin—pancreatic cancer	0.00027	0.00068	CcSEcCtD
Metoprolol—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000269	0.000679	CcSEcCtD
Metoprolol—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000269	0.000677	CcSEcCtD
Metoprolol—Flatulence—Epirubicin—pancreatic cancer	0.000268	0.000676	CcSEcCtD
Metoprolol—Tension—Epirubicin—pancreatic cancer	0.000267	0.000673	CcSEcCtD
Metoprolol—Dysgeusia—Epirubicin—pancreatic cancer	0.000267	0.000672	CcSEcCtD
Metoprolol—Nervousness—Epirubicin—pancreatic cancer	0.000264	0.000666	CcSEcCtD
Metoprolol—Angiopathy—Doxorubicin—pancreatic cancer	0.000263	0.000662	CcSEcCtD
Metoprolol—Muscle spasms—Epirubicin—pancreatic cancer	0.000262	0.00066	CcSEcCtD
Metoprolol—Immune system disorder—Doxorubicin—pancreatic cancer	0.000261	0.000659	CcSEcCtD
Metoprolol—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000261	0.000657	CcSEcCtD
Metoprolol—Abdominal pain—Docetaxel—pancreatic cancer	0.00026	0.000656	CcSEcCtD
Metoprolol—Body temperature increased—Docetaxel—pancreatic cancer	0.00026	0.000656	CcSEcCtD
Metoprolol—Arrhythmia—Doxorubicin—pancreatic cancer	0.000259	0.000651	CcSEcCtD
Metoprolol—Vision blurred—Epirubicin—pancreatic cancer	0.000257	0.000647	CcSEcCtD
Metoprolol—Alopecia—Doxorubicin—pancreatic cancer	0.000256	0.000644	CcSEcCtD
Metoprolol—Mental disorder—Doxorubicin—pancreatic cancer	0.000254	0.000639	CcSEcCtD
Metoprolol—Flatulence—Doxorubicin—pancreatic cancer	0.000248	0.000626	CcSEcCtD
Metoprolol—Tension—Doxorubicin—pancreatic cancer	0.000247	0.000623	CcSEcCtD
Metoprolol—Dysgeusia—Doxorubicin—pancreatic cancer	0.000247	0.000622	CcSEcCtD
Metoprolol—Nervousness—Doxorubicin—pancreatic cancer	0.000245	0.000617	CcSEcCtD
Metoprolol—Vertigo—Epirubicin—pancreatic cancer	0.000245	0.000616	CcSEcCtD
Metoprolol—Syncope—Epirubicin—pancreatic cancer	0.000244	0.000615	CcSEcCtD
Metoprolol—Leukopenia—Epirubicin—pancreatic cancer	0.000244	0.000614	CcSEcCtD
Metoprolol—Hypersensitivity—Docetaxel—pancreatic cancer	0.000243	0.000612	CcSEcCtD
Metoprolol—Muscle spasms—Doxorubicin—pancreatic cancer	0.000242	0.00061	CcSEcCtD
Metoprolol—Palpitations—Epirubicin—pancreatic cancer	0.000241	0.000606	CcSEcCtD
Metoprolol—Loss of consciousness—Epirubicin—pancreatic cancer	0.000239	0.000603	CcSEcCtD
Metoprolol—Vision blurred—Doxorubicin—pancreatic cancer	0.000237	0.000598	CcSEcCtD
Metoprolol—Asthenia—Docetaxel—pancreatic cancer	0.000236	0.000596	CcSEcCtD
Metoprolol—Hypertension—Epirubicin—pancreatic cancer	0.000235	0.000592	CcSEcCtD
Metoprolol—Pruritus—Docetaxel—pancreatic cancer	0.000233	0.000587	CcSEcCtD
Metoprolol—Chest pain—Epirubicin—pancreatic cancer	0.000232	0.000584	CcSEcCtD
Metoprolol—Arthralgia—Epirubicin—pancreatic cancer	0.000232	0.000584	CcSEcCtD
Metoprolol—Anxiety—Epirubicin—pancreatic cancer	0.000231	0.000582	CcSEcCtD
Metoprolol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.00023	0.00058	CcSEcCtD
Metoprolol—Dry mouth—Epirubicin—pancreatic cancer	0.000227	0.000571	CcSEcCtD
Metoprolol—Vertigo—Doxorubicin—pancreatic cancer	0.000226	0.00057	CcSEcCtD
Metoprolol—Syncope—Doxorubicin—pancreatic cancer	0.000226	0.000569	CcSEcCtD
Metoprolol—Leukopenia—Doxorubicin—pancreatic cancer	0.000226	0.000568	CcSEcCtD
Metoprolol—Diarrhoea—Docetaxel—pancreatic cancer	0.000225	0.000568	CcSEcCtD
Metoprolol—Confusional state—Epirubicin—pancreatic cancer	0.000224	0.000565	CcSEcCtD
Metoprolol—Palpitations—Doxorubicin—pancreatic cancer	0.000223	0.000561	CcSEcCtD
Metoprolol—Oedema—Epirubicin—pancreatic cancer	0.000222	0.00056	CcSEcCtD
Metoprolol—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000221	0.000558	CcSEcCtD
Metoprolol—Shock—Epirubicin—pancreatic cancer	0.000219	0.000551	CcSEcCtD
Metoprolol—Nervous system disorder—Epirubicin—pancreatic cancer	0.000218	0.000549	CcSEcCtD
Metoprolol—Dizziness—Docetaxel—pancreatic cancer	0.000218	0.000549	CcSEcCtD
Metoprolol—Thrombocytopenia—Epirubicin—pancreatic cancer	0.000218	0.000548	CcSEcCtD
Metoprolol—Hypertension—Doxorubicin—pancreatic cancer	0.000218	0.000548	CcSEcCtD
Metoprolol—Tachycardia—Epirubicin—pancreatic cancer	0.000217	0.000546	CcSEcCtD
Metoprolol—Skin disorder—Epirubicin—pancreatic cancer	0.000216	0.000544	CcSEcCtD
Metoprolol—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000215	0.000541	CcSEcCtD
Metoprolol—Arthralgia—Doxorubicin—pancreatic cancer	0.000214	0.00054	CcSEcCtD
Metoprolol—Chest pain—Doxorubicin—pancreatic cancer	0.000214	0.00054	CcSEcCtD
Metoprolol—Anxiety—Doxorubicin—pancreatic cancer	0.000214	0.000539	CcSEcCtD
Metoprolol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000213	0.000537	CcSEcCtD
Metoprolol—Dry mouth—Doxorubicin—pancreatic cancer	0.00021	0.000529	CcSEcCtD
Metoprolol—Vomiting—Docetaxel—pancreatic cancer	0.000209	0.000528	CcSEcCtD
Metoprolol—Rash—Docetaxel—pancreatic cancer	0.000208	0.000523	CcSEcCtD
Metoprolol—Hypotension—Epirubicin—pancreatic cancer	0.000208	0.000523	CcSEcCtD
Metoprolol—Dermatitis—Docetaxel—pancreatic cancer	0.000208	0.000523	CcSEcCtD
Metoprolol—Confusional state—Doxorubicin—pancreatic cancer	0.000207	0.000522	CcSEcCtD
Metoprolol—Headache—Docetaxel—pancreatic cancer	0.000206	0.00052	CcSEcCtD
Metoprolol—Oedema—Doxorubicin—pancreatic cancer	0.000206	0.000518	CcSEcCtD
Metoprolol—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000202	0.00051	CcSEcCtD
Metoprolol—Shock—Doxorubicin—pancreatic cancer	0.000202	0.00051	CcSEcCtD
Metoprolol—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000202	0.000508	CcSEcCtD
Metoprolol—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.000201	0.000507	CcSEcCtD
Metoprolol—Insomnia—Epirubicin—pancreatic cancer	0.000201	0.000506	CcSEcCtD
Metoprolol—Tachycardia—Doxorubicin—pancreatic cancer	0.000201	0.000506	CcSEcCtD
Metoprolol—Skin disorder—Doxorubicin—pancreatic cancer	0.0002	0.000503	CcSEcCtD
Metoprolol—Paraesthesia—Epirubicin—pancreatic cancer	0.0002	0.000503	CcSEcCtD
Metoprolol—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000199	0.000501	CcSEcCtD
Metoprolol—Dyspnoea—Epirubicin—pancreatic cancer	0.000198	0.000499	CcSEcCtD
Metoprolol—Somnolence—Epirubicin—pancreatic cancer	0.000198	0.000498	CcSEcCtD
Metoprolol—Nausea—Docetaxel—pancreatic cancer	0.000196	0.000493	CcSEcCtD
Metoprolol—Dyspepsia—Epirubicin—pancreatic cancer	0.000196	0.000493	CcSEcCtD
Metoprolol—Hypotension—Doxorubicin—pancreatic cancer	0.000192	0.000484	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000192	0.000483	CcSEcCtD
Metoprolol—Fatigue—Epirubicin—pancreatic cancer	0.000192	0.000483	CcSEcCtD
Metoprolol—Constipation—Epirubicin—pancreatic cancer	0.00019	0.000479	CcSEcCtD
Metoprolol—Pain—Epirubicin—pancreatic cancer	0.00019	0.000479	CcSEcCtD
Metoprolol—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000187	0.000472	CcSEcCtD
Metoprolol—Insomnia—Doxorubicin—pancreatic cancer	0.000186	0.000469	CcSEcCtD
Metoprolol—Paraesthesia—Doxorubicin—pancreatic cancer	0.000185	0.000465	CcSEcCtD
Metoprolol—Dyspnoea—Doxorubicin—pancreatic cancer	0.000183	0.000462	CcSEcCtD
Metoprolol—Feeling abnormal—Epirubicin—pancreatic cancer	0.000183	0.000461	CcSEcCtD
Metoprolol—Somnolence—Doxorubicin—pancreatic cancer	0.000183	0.000461	CcSEcCtD
Metoprolol—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000182	0.000458	CcSEcCtD
Metoprolol—Dyspepsia—Doxorubicin—pancreatic cancer	0.000181	0.000456	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000178	0.000447	CcSEcCtD
Metoprolol—Fatigue—Doxorubicin—pancreatic cancer	0.000177	0.000447	CcSEcCtD
Metoprolol—Urticaria—Epirubicin—pancreatic cancer	0.000177	0.000445	CcSEcCtD
Metoprolol—Pain—Doxorubicin—pancreatic cancer	0.000176	0.000443	CcSEcCtD
Metoprolol—Constipation—Doxorubicin—pancreatic cancer	0.000176	0.000443	CcSEcCtD
Metoprolol—Body temperature increased—Epirubicin—pancreatic cancer	0.000176	0.000443	CcSEcCtD
Metoprolol—Abdominal pain—Epirubicin—pancreatic cancer	0.000176	0.000443	CcSEcCtD
Metoprolol—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000169	0.000427	CcSEcCtD
Metoprolol—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000168	0.000424	CcSEcCtD
Metoprolol—Hypersensitivity—Epirubicin—pancreatic cancer	0.000164	0.000413	CcSEcCtD
Metoprolol—Urticaria—Doxorubicin—pancreatic cancer	0.000163	0.000412	CcSEcCtD
Metoprolol—Abdominal pain—Doxorubicin—pancreatic cancer	0.000163	0.00041	CcSEcCtD
Metoprolol—Body temperature increased—Doxorubicin—pancreatic cancer	0.000163	0.00041	CcSEcCtD
Metoprolol—Asthenia—Epirubicin—pancreatic cancer	0.000159	0.000402	CcSEcCtD
Metoprolol—Pruritus—Epirubicin—pancreatic cancer	0.000157	0.000396	CcSEcCtD
Metoprolol—Diarrhoea—Epirubicin—pancreatic cancer	0.000152	0.000383	CcSEcCtD
Metoprolol—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000151	0.000382	CcSEcCtD
Metoprolol—Asthenia—Doxorubicin—pancreatic cancer	0.000148	0.000372	CcSEcCtD
Metoprolol—Dizziness—Epirubicin—pancreatic cancer	0.000147	0.00037	CcSEcCtD
Metoprolol—Pruritus—Doxorubicin—pancreatic cancer	0.000145	0.000367	CcSEcCtD
Metoprolol—Vomiting—Epirubicin—pancreatic cancer	0.000141	0.000356	CcSEcCtD
Metoprolol—Diarrhoea—Doxorubicin—pancreatic cancer	0.000141	0.000354	CcSEcCtD
Metoprolol—Rash—Epirubicin—pancreatic cancer	0.00014	0.000353	CcSEcCtD
Metoprolol—Dermatitis—Epirubicin—pancreatic cancer	0.00014	0.000353	CcSEcCtD
Metoprolol—Headache—Epirubicin—pancreatic cancer	0.000139	0.000351	CcSEcCtD
Metoprolol—Dizziness—Doxorubicin—pancreatic cancer	0.000136	0.000343	CcSEcCtD
Metoprolol—Nausea—Epirubicin—pancreatic cancer	0.000132	0.000333	CcSEcCtD
Metoprolol—Vomiting—Doxorubicin—pancreatic cancer	0.000131	0.000329	CcSEcCtD
Metoprolol—Rash—Doxorubicin—pancreatic cancer	0.00013	0.000327	CcSEcCtD
Metoprolol—Dermatitis—Doxorubicin—pancreatic cancer	0.00013	0.000326	CcSEcCtD
Metoprolol—Headache—Doxorubicin—pancreatic cancer	0.000129	0.000325	CcSEcCtD
Metoprolol—Nausea—Doxorubicin—pancreatic cancer	0.000122	0.000308	CcSEcCtD
Metoprolol—ADRB2—Signaling Pathways—DTX4—pancreatic cancer	1.58e-05	0.00117	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—GLI1—pancreatic cancer	1.58e-05	0.00117	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PPP2R5B—pancreatic cancer	1.57e-05	0.00116	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—NRP1—pancreatic cancer	1.57e-05	0.00116	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—AGTR1—pancreatic cancer	1.57e-05	0.00116	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—CNR1—pancreatic cancer	1.55e-05	0.00114	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—NRP1—pancreatic cancer	1.54e-05	0.00114	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PPP2R5B—pancreatic cancer	1.54e-05	0.00114	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—GCG—pancreatic cancer	1.53e-05	0.00113	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—HEY2—pancreatic cancer	1.51e-05	0.00112	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—GCG—pancreatic cancer	1.49e-05	0.0011	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—GLP1R—pancreatic cancer	1.48e-05	0.0011	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—HEY2—pancreatic cancer	1.48e-05	0.00109	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—GAST—pancreatic cancer	1.48e-05	0.00109	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—DPYD—pancreatic cancer	1.46e-05	0.00108	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—AGTR1—pancreatic cancer	1.46e-05	0.00108	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—GAST—pancreatic cancer	1.44e-05	0.00107	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—AGTR1—pancreatic cancer	1.42e-05	0.00105	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—SCT—pancreatic cancer	1.4e-05	0.00104	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—HEY1—pancreatic cancer	1.4e-05	0.00104	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—SLC2A2—pancreatic cancer	1.38e-05	0.00102	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—SCT—pancreatic cancer	1.37e-05	0.00101	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—HEY1—pancreatic cancer	1.37e-05	0.00101	CbGpPWpGaD
Metoprolol—SLC22A2—Transmission across Chemical Synapses—HRAS—pancreatic cancer	1.36e-05	0.00101	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—pancreatic cancer	1.36e-05	0.001	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PRSS1—pancreatic cancer	1.36e-05	0.001	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CCK—pancreatic cancer	1.34e-05	0.000987	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PRSS1—pancreatic cancer	1.32e-05	0.000979	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CCK—pancreatic cancer	1.31e-05	0.000966	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CNR2—pancreatic cancer	1.3e-05	0.000962	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—GLP1R—pancreatic cancer	1.3e-05	0.000962	CbGpPWpGaD
Metoprolol—ADRB1—GPCR ligand binding—CXCL8—pancreatic cancer	1.3e-05	0.000962	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CCKAR—pancreatic cancer	1.28e-05	0.000947	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CNR2—pancreatic cancer	1.27e-05	0.000941	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—GLP1R—pancreatic cancer	1.27e-05	0.000941	CbGpPWpGaD
Metoprolol—ADRB2—GPCR ligand binding—CXCL8—pancreatic cancer	1.27e-05	0.000941	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—pancreatic cancer	1.26e-05	0.000933	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CCKAR—pancreatic cancer	1.25e-05	0.000926	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PRSS1—pancreatic cancer	1.25e-05	0.000923	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—JAG2—pancreatic cancer	1.24e-05	0.000918	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—pancreatic cancer	1.23e-05	0.000908	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—MEN1—pancreatic cancer	1.22e-05	0.000905	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—pancreatic cancer	1.22e-05	0.000899	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—JAG2—pancreatic cancer	1.21e-05	0.000898	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—MEN1—pancreatic cancer	1.2e-05	0.000885	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—pancreatic cancer	1.19e-05	0.000876	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—ARG2—pancreatic cancer	1.18e-05	0.00087	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—SHH—pancreatic cancer	1.17e-05	0.000863	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—NOTCH4—pancreatic cancer	1.16e-05	0.000858	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—IAPP—pancreatic cancer	1.15e-05	0.000852	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—ARG2—pancreatic cancer	1.15e-05	0.000849	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—SHH—pancreatic cancer	1.14e-05	0.000844	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—NOTCH4—pancreatic cancer	1.13e-05	0.000839	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—IAPP—pancreatic cancer	1.13e-05	0.000834	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PTCH1—pancreatic cancer	1.11e-05	0.000818	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PTHLH—pancreatic cancer	1.11e-05	0.000818	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—pancreatic cancer	1.1e-05	0.000813	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PTHLH—pancreatic cancer	1.08e-05	0.0008	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PTCH1—pancreatic cancer	1.08e-05	0.0008	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—ARG2—pancreatic cancer	1.08e-05	0.0008	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—CD44—pancreatic cancer	1.07e-05	0.000792	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—pancreatic cancer	1.07e-05	0.000792	CbGpPWpGaD
Metoprolol—SLC22A2—Neuronal System—HRAS—pancreatic cancer	1.05e-05	0.000773	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—TYMP—pancreatic cancer	1.03e-05	0.00076	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—GCG—pancreatic cancer	1.03e-05	0.000759	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—SST—pancreatic cancer	1.01e-05	0.000748	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—TYMP—pancreatic cancer	1e-05	0.000742	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—PIK3CG—pancreatic cancer	9.98e-06	0.000738	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—JAG1—pancreatic cancer	9.9e-06	0.000732	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—SST—pancreatic cancer	9.9e-06	0.000732	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—NOTCH3—pancreatic cancer	9.86e-06	0.000729	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—pancreatic cancer	9.85e-06	0.000728	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—pancreatic cancer	9.83e-06	0.000727	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—PIK3CG—pancreatic cancer	9.76e-06	0.000722	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—JAG1—pancreatic cancer	9.69e-06	0.000716	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—STK11—pancreatic cancer	9.65e-06	0.000714	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—NOTCH3—pancreatic cancer	9.65e-06	0.000713	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—pancreatic cancer	9.63e-06	0.000712	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—TYMP—pancreatic cancer	9.46e-06	0.000699	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CNR1—pancreatic cancer	9.34e-06	0.000691	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—pancreatic cancer	9.18e-06	0.000678	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CNR1—pancreatic cancer	9.14e-06	0.000676	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—pancreatic cancer	9.1e-06	0.000673	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—PIK3CG—pancreatic cancer	9.06e-06	0.00067	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—GCG—pancreatic cancer	9.02e-06	0.000667	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—PIK3CG—pancreatic cancer	8.87e-06	0.000656	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—GCG—pancreatic cancer	8.82e-06	0.000652	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—PIK3CD—pancreatic cancer	8.77e-06	0.000649	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—AGTR1—pancreatic cancer	8.61e-06	0.000636	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—PIK3CD—pancreatic cancer	8.58e-06	0.000635	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	8.49e-06	0.000628	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—STK11—pancreatic cancer	8.48e-06	0.000627	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—AGTR1—pancreatic cancer	8.42e-06	0.000622	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—pancreatic cancer	8.36e-06	0.000618	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—TYMS—pancreatic cancer	8.3e-06	0.000614	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—STK11—pancreatic cancer	8.3e-06	0.000613	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GLP1R—pancreatic cancer	8.29e-06	0.000613	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—DPYD—pancreatic cancer	8.16e-06	0.000603	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GLP1R—pancreatic cancer	8.09e-06	0.000598	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	8.09e-06	0.000598	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—PIK3CD—pancreatic cancer	7.97e-06	0.000589	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—DPYD—pancreatic cancer	7.96e-06	0.000589	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—PIK3CD—pancreatic cancer	7.79e-06	0.000576	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—SLC2A2—pancreatic cancer	7.74e-06	0.000572	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	7.66e-06	0.000566	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—PIK3CB—pancreatic cancer	7.65e-06	0.000566	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GLP1R—pancreatic cancer	7.62e-06	0.000564	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—SLC2A2—pancreatic cancer	7.55e-06	0.000559	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—DPYD—pancreatic cancer	7.5e-06	0.000555	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—PIK3CB—pancreatic cancer	7.48e-06	0.000553	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—SMAD4—pancreatic cancer	7.43e-06	0.000549	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	7.39e-06	0.000547	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—CXCL8—pancreatic cancer	7.35e-06	0.000543	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—SMAD4—pancreatic cancer	7.27e-06	0.000537	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—HES1—pancreatic cancer	7.25e-06	0.000536	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—CXCL8—pancreatic cancer	7.19e-06	0.000532	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—SLC2A2—pancreatic cancer	7.12e-06	0.000526	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—HES1—pancreatic cancer	7.09e-06	0.000525	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—PIK3CB—pancreatic cancer	6.95e-06	0.000514	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	6.83e-06	0.000505	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—PIK3CB—pancreatic cancer	6.79e-06	0.000502	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—APOE—pancreatic cancer	6.75e-06	0.000499	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	6.73e-06	0.000498	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—CXCL8—pancreatic cancer	6.67e-06	0.000494	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—CXCL8—pancreatic cancer	6.53e-06	0.000483	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—TERT—pancreatic cancer	6.36e-06	0.00047	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—TERT—pancreatic cancer	6.22e-06	0.00046	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PIK3CG—pancreatic cancer	6.09e-06	0.000451	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—HIF1A—pancreatic cancer	6.08e-06	0.000449	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—TSC2—pancreatic cancer	6.06e-06	0.000448	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—CD44—pancreatic cancer	5.99e-06	0.000443	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—HIF1A—pancreatic cancer	5.95e-06	0.00044	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—APOE—pancreatic cancer	5.93e-06	0.000439	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—TSC2—pancreatic cancer	5.93e-06	0.000439	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PPARG—pancreatic cancer	5.88e-06	0.000435	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	5.87e-06	0.000434	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—CD44—pancreatic cancer	5.85e-06	0.000433	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	5.81e-06	0.00043	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—KDR—pancreatic cancer	5.81e-06	0.00043	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—APOE—pancreatic cancer	5.8e-06	0.000429	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GCG—pancreatic cancer	5.75e-06	0.000425	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—KDR—pancreatic cancer	5.69e-06	0.00042	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GCG—pancreatic cancer	5.61e-06	0.000415	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—NFKBIA—pancreatic cancer	5.53e-06	0.000409	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—CD44—pancreatic cancer	5.51e-06	0.000408	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—NOTCH1—pancreatic cancer	5.48e-06	0.000405	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—NFKBIA—pancreatic cancer	5.41e-06	0.0004	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—STK11—pancreatic cancer	5.4e-06	0.000399	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PIK3CD—pancreatic cancer	5.36e-06	0.000396	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—NOTCH1—pancreatic cancer	5.36e-06	0.000396	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PIK3CG—pancreatic cancer	5.35e-06	0.000396	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—NRAS—pancreatic cancer	5.35e-06	0.000396	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—EGF—pancreatic cancer	5.29e-06	0.000391	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GCG—pancreatic cancer	5.28e-06	0.000391	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—STK11—pancreatic cancer	5.27e-06	0.00039	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PIK3CG—pancreatic cancer	5.24e-06	0.000387	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—NRAS—pancreatic cancer	5.24e-06	0.000387	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—EGF—pancreatic cancer	5.18e-06	0.000383	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	5.07e-06	0.000375	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—STK11—pancreatic cancer	4.97e-06	0.000367	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—EGFR—pancreatic cancer	4.88e-06	0.000361	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—EGFR—pancreatic cancer	4.77e-06	0.000353	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PIK3CD—pancreatic cancer	4.71e-06	0.000348	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PIK3CB—pancreatic cancer	4.67e-06	0.000345	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—PIK3CA—pancreatic cancer	4.66e-06	0.000345	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—TYMS—pancreatic cancer	4.65e-06	0.000344	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PTGS2—pancreatic cancer	4.63e-06	0.000342	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—KRAS—pancreatic cancer	4.61e-06	0.000341	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PIK3CD—pancreatic cancer	4.6e-06	0.00034	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—PIK3CA—pancreatic cancer	4.56e-06	0.000337	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—TYMS—pancreatic cancer	4.54e-06	0.000335	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—KRAS—pancreatic cancer	4.51e-06	0.000333	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—TYMS—pancreatic cancer	4.27e-06	0.000316	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—PIK3CA—pancreatic cancer	4.23e-06	0.000313	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—PIK3CA—pancreatic cancer	4.14e-06	0.000306	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PIK3CB—pancreatic cancer	4.1e-06	0.000303	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PTEN—pancreatic cancer	4.03e-06	0.000298	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PIK3CB—pancreatic cancer	4.01e-06	0.000297	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CXCL8—pancreatic cancer	3.94e-06	0.000292	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—HRAS—pancreatic cancer	3.92e-06	0.00029	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CXCL8—pancreatic cancer	3.86e-06	0.000285	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—HRAS—pancreatic cancer	3.83e-06	0.000283	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—AKT1—pancreatic cancer	3.81e-06	0.000282	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—APOE—pancreatic cancer	3.78e-06	0.000279	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CASP3—pancreatic cancer	3.77e-06	0.000279	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—AKT1—pancreatic cancer	3.73e-06	0.000276	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CASP3—pancreatic cancer	3.69e-06	0.000273	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—APOE—pancreatic cancer	3.69e-06	0.000273	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CCND1—pancreatic cancer	3.67e-06	0.000272	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CTNNB1—pancreatic cancer	3.64e-06	0.000269	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CCND1—pancreatic cancer	3.59e-06	0.000266	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	3.58e-06	0.000265	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—MMP9—pancreatic cancer	3.57e-06	0.000264	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CTNNB1—pancreatic cancer	3.56e-06	0.000263	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PTEN—pancreatic cancer	3.55e-06	0.000262	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—MMP9—pancreatic cancer	3.49e-06	0.000258	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—APOE—pancreatic cancer	3.48e-06	0.000257	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PTEN—pancreatic cancer	3.47e-06	0.000256	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—AKT1—pancreatic cancer	3.46e-06	0.000256	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PIK3CG—pancreatic cancer	3.41e-06	0.000252	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—AKT1—pancreatic cancer	3.38e-06	0.00025	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PIK3CG—pancreatic cancer	3.33e-06	0.000246	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PPARG—pancreatic cancer	3.29e-06	0.000243	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—SRC—pancreatic cancer	3.29e-06	0.000243	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—SRC—pancreatic cancer	3.22e-06	0.000238	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PPARG—pancreatic cancer	3.21e-06	0.000238	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—VEGFA—pancreatic cancer	3.2e-06	0.000237	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—STAT3—pancreatic cancer	3.17e-06	0.000234	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—NRAS—pancreatic cancer	3.16e-06	0.000234	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	3.14e-06	0.000232	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—VEGFA—pancreatic cancer	3.13e-06	0.000232	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—STAT3—pancreatic cancer	3.1e-06	0.000229	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—NRAS—pancreatic cancer	3.09e-06	0.000229	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PPARG—pancreatic cancer	3.03e-06	0.000224	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PIK3CD—pancreatic cancer	3e-06	0.000222	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—MYC—pancreatic cancer	2.95e-06	0.000218	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—TGFB1—pancreatic cancer	2.94e-06	0.000217	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PIK3CD—pancreatic cancer	2.93e-06	0.000216	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—MYC—pancreatic cancer	2.88e-06	0.000213	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—EGFR—pancreatic cancer	2.88e-06	0.000213	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—TGFB1—pancreatic cancer	2.88e-06	0.000213	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PIK3CA—pancreatic cancer	2.85e-06	0.00021	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—EGFR—pancreatic cancer	2.82e-06	0.000208	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	2.76e-06	0.000204	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—KRAS—pancreatic cancer	2.72e-06	0.000201	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—KRAS—pancreatic cancer	2.66e-06	0.000197	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PIK3CB—pancreatic cancer	2.61e-06	0.000193	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PTGS2—pancreatic cancer	2.59e-06	0.000191	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PIK3CB—pancreatic cancer	2.55e-06	0.000189	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PTGS2—pancreatic cancer	2.53e-06	0.000187	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PIK3CA—pancreatic cancer	2.5e-06	0.000185	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PIK3CA—pancreatic cancer	2.45e-06	0.000181	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—TP53—pancreatic cancer	2.42e-06	0.000179	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	2.4e-06	0.000178	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PTGS2—pancreatic cancer	2.38e-06	0.000176	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—TP53—pancreatic cancer	2.37e-06	0.000175	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—AKT1—pancreatic cancer	2.33e-06	0.000172	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—HRAS—pancreatic cancer	2.31e-06	0.000171	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—HRAS—pancreatic cancer	2.26e-06	0.000167	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PTEN—pancreatic cancer	2.26e-06	0.000167	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PTEN—pancreatic cancer	2.2e-06	0.000163	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PTEN—pancreatic cancer	2.08e-06	0.000154	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—AKT1—pancreatic cancer	2.04e-06	0.000151	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—AKT1—pancreatic cancer	2e-06	0.000148	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PIK3CA—pancreatic cancer	1.59e-06	0.000118	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PIK3CA—pancreatic cancer	1.56e-06	0.000115	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	1.47e-06	0.000108	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—AKT1—pancreatic cancer	1.3e-06	9.62e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—AKT1—pancreatic cancer	1.27e-06	9.39e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—AKT1—pancreatic cancer	1.2e-06	8.85e-05	CbGpPWpGaD
